Revolution Medicines Inc. (RVMD)
Summary
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.
Revolution Medicines Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 2 | $159 | $367.95 | $208.95 | 131.42% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 44,900 | $4.31M | $8.26M | $3.95M | 91.57% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 110 | $10,697.5 | $20,242.2 | $9,544.7 | 89.22% |
 Farallon Capital Farallon Capital Management LLC | 13.6M | $472.3M | $2.51B | $2.04B | 431.03% |
 John H. Burbank III Passport Capital LLC | 9.56M | $294.87M | $1.76B | $1.46B | 496.35% |
Revolution Medicines Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robert Driscoll Wedbush | 62 | $9,370.88 | $11,535.79 | $2,164.91 | 23.1% |
| EFV Eva Fortea Verdejo Wells Fargo | 47.18 | $4,767.34 | $8,778.53 | $4,011.19 | 84.14% |
| GR Gregory Renza Truist Securities | 193.52 | $14,104.58 | $35,693 | $21,588.42 | 153.06% |
Revolution Medicines Inc. (RVMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revolution Medicines Inc. ever had a stock split?
Revolution Medicines Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Goldsmith CEO | NASDAQ (NGS) Exchange | 76155X100 CUSIP |
| US Country | 883 Employees | - Last Dividend | - Last Split | 13 Feb 2020 IPO Date |
Overview
Revolution Medicines, Inc. is a clinical-stage company that focuses on precision oncology, specifically targeting RAS-addicted cancers, which are notoriously challenging to treat. The company leverages its expertise in the field to develop innovative therapies designed to inhibit the RAS signaling pathway, a critical driver in many forms of cancer. With a research and development pipeline featuring a variety of RAS(ON) inhibitors and RAS companion inhibitors, Revolution Medicines employs both monotherapy and combination treatment strategies to potentially improve outcomes for patients with these aggressive cancers. Founded in 2014, the company is headquartered in Redwood City, California, positioning itself at the forefront of cancer research with a clear focus on addressing unmet medical needs in the oncology space.
Products and Services
- RMC-6236 (multi): This RAS(ON) inhibitor is currently in phase 1 clinical trial. It exemplifies the company's approach to developing targeted therapies that can be used both as standalone treatments and in combination with other inhibitors or therapeutic agents.
- RMC-6291 (G12C): Also in phase 1 clinical trials, RMC-6291 targets specific mutations within the RAS gene, showcasing Revolution Medicines' commitment to precision oncology by tailoring treatments to the genetic profile of a patient's cancer.
- RMC-9805 (G12D): This development candidate is another example of the company's RAS(ON) inhibitors, focusing on a distinct mutation and currently undergoing phase 1 clinical trials to evaluate its effectiveness and safety.
- Development Candidates (RMC-5127, RMC-0708, RMC-8839): These candidates, including RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), are in various stages of pre-clinical and early clinical development. They represent the next wave of potential treatments targeting a variety of RAS mutations.
- RAS Companion Inhibitors (RMC-4630, RMC-5552):
- RMC-4630 is currently in phase 2 clinical trials. It exemplifies the company's efforts to develop drugs that can be used in combination with their RAS(ON) inhibitors to provide comprehensive treatment solutions.
- RMC-5552 is in phase 1 clinical trial, further expanding the range of the company's portfolio with the goal of offering more effective combination therapy options for patients fighting RAS-addicted cancers.
